Geneva Capital Management LLC Purchases 579,349 Shares of Certara, Inc. (NASDAQ:CERT)

Geneva Capital Management LLC raised its position in shares of Certara, Inc. (NASDAQ:CERT) by 15.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,404,199 shares of the company’s stock after purchasing an additional 579,349 shares during the quarter. Certara accounts for about 1.4% of Geneva Capital Management LLC’s investment portfolio, making the stock its 25th largest position. Geneva Capital Management LLC’s holdings in Certara were worth $78,747,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mubadala Investment Co PJSC purchased a new position in shares of Certara during the 4th quarter valued at $169,135,000. Wasatch Advisors LP lifted its position in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after acquiring an additional 932,598 shares in the last quarter. Norges Bank bought a new position in shares of Certara in the fourth quarter worth about $14,262,000. Massachusetts Financial Services Co. MA grew its position in shares of Certara by 22.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,585,155 shares of the company’s stock worth $45,473,000 after purchasing an additional 475,081 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. raised its stake in Certara by 93.1% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock valued at $13,532,000 after purchasing an additional 370,820 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. KeyCorp dropped their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday. Finally, Barclays reduced their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Seven investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average target price of $19.44.

Certara Price Performance

CERT stock traded up $1.24 during trading on Thursday, hitting $15.12. 671,269 shares of the company’s stock traded hands, compared to its average volume of 559,641. Certara, Inc. has a 52 week low of $11.81 and a 52 week high of $19.87. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of -38.44, a P/E/G ratio of 4.93 and a beta of 1.52. The business has a fifty day simple moving average of $15.58 and a 200 day simple moving average of $16.70. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The business had revenue of $96.65 million during the quarter, compared to the consensus estimate of $94.48 million. As a group, research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.